Clinical trials
Completed Polymyositis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
41 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 41 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Karolinska Institutet | 4 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 4 |
| Amgen | 3 |
| Kezar Life Sciences, Inc. | 2 |
| National Institute of Environmental Health Sciences (NIEHS) | 2 |
| University Hospital, Rouen | 2 |
| University of Pittsburgh | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Bristol-Myers Squibb | 1 |
| Chester Oddis | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Polymyositis | 41 |
| Dermatomyositis | 37 |
| Myositis | 19 |
| Myositis, Inclusion Body | 6 |
| Connective Tissue Diseases | 3 |
| Lupus Erythematosus, Systemic | 3 |
| Muscular Diseases | 3 |
| Sjogren's Syndrome | 3 |
| Arthritis, Rheumatoid | 2 |
| Autoimmune Diseases | 2 |
Trials
Showing 26 to 41 of 41. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.